<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34316024</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-0366</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Genetics in medicine : official journal of the American College of Medical Genetics</Title>
          <ISOAbbreviation>Genet Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension.</ArticleTitle>
        <Pagination>
          <StartPage>2426</StartPage>
          <EndPage>2432</EndPage>
          <MedlinePgn>2426-2432</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41436-021-01282-y</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">To assess the efficacy of tasimelteon to improve sleep in Smith-Magenis syndrome (SMS).</AbstractText>
          <AbstractText Label="METHODS">A 9-week, double-blind, randomized, two-period crossover study was conducted at four US clinical centers. Genetically confirmed patients with SMS, aged 3 to 39, with sleep complaints participated in the study. Patients were assigned to treatment with tasimelteon or placebo in a 4-week crossover study with a 1-week washout between treatments. Eligible patients participated in an open-label study and were followed for &gt;3 months.</AbstractText>
          <AbstractText Label="RESULTS">Improvement of sleep quality (DDSQ50) and total sleep time (DDTST50) on the worst 50% of nights were primary endpoints. Secondary measures included actigraphy and behavioral parameters. Over three years, 52 patients were screened, and 25 patients completed the randomized portion of the study. DDSQ50 significantly improved over placebo (0.4, p = 0.0139), and DDTST50 also improved (18.5 minutes, p = 0.0556). Average sleep quality (0.3, p = 0.0155) and actigraphy-based total sleep time (21.1 minutes, p = 0.0134) improved significantly, consistent with the primary outcomes. Patients treated for ≥90 days in the open-label study showed persistent efficacy. Adverse events were similar between placebo and tasimelteon.</AbstractText>
          <AbstractText Label="CONCLUSION">Tasimelteon safely and effectively improved sleep in SMS.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Polymeropoulos</LastName>
            <ForeName>Christos M</ForeName>
            <Initials>CM</Initials>
            <Identifier Source="ORCID">0000-0002-8006-0454</Identifier>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brooks</LastName>
            <ForeName>Justin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Czeisler</LastName>
            <ForeName>Emily L</ForeName>
            <Initials>EL</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fisher</LastName>
            <ForeName>Michaela A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gibson</LastName>
            <ForeName>Mary M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kite</LastName>
            <ForeName>Kailey</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smieszek</LastName>
            <ForeName>Sandra P</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA. sandra.smieszek@vandapharma.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Changfu</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elsea</LastName>
            <ForeName>Sarah H</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birznieks</LastName>
            <ForeName>Gunther</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Polymeropoulos</LastName>
            <ForeName>Mihael H</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Vanda Pharmaceuticals Inc., Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Genet Med</MedlineTA>
        <NlmUniqueID>9815831</NlmUniqueID>
        <ISSNLinking>1098-3600</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SHS4PU80D9</RegistryNumber>
          <NameOfSubstance UI="C478745">tasimelteon</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058496" MajorTopicYN="Y">Smith-Magenis Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>C.M.P., J.B., E.L.C., M.A.F., M.M.G., K.K., S.P.S., C.X., G.B., M.H.P. are employees of Vanda Pharmaceuticals. M.H.P. is Chief Executive Officer of Vanda Pharmaceuticals. S.H.E. declares no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34316024</ArticleId>
        <ArticleId IdType="pmc">PMC8629754</ArticleId>
        <ArticleId IdType="doi">10.1038/s41436-021-01282-y</ArticleId>
        <ArticleId IdType="pii">S1098-3600(21)05444-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH. Mutations in RAI1 associated with Smith–Magenis syndrome. Nat Genet. 2003;33:466–8. doi: 10.1038/ng1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1126</ArticleId>
            <ArticleId IdType="pubmed">12652298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg F, Guzzetta V, Montes de Oca-Luna R, Magenis RE, Smith AC, Richter SF, et al.  Molecular analysis of the Smith–Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2) Am J Hum Genet. 1991;49:1207–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1686451</ArticleId>
            <ArticleId IdType="pubmed">1746552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith AC, Magenis RE, Elsea SH. Overview of Smith–Magenis syndrome. J Assoc Genet Technol. 2005;31:163–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16354942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potocki L, Shaw CJ, Stankiewicz P, Lupski JR. Variability in clinical phenotype despite common chromosomal deletion in Smith–Magenis syndrome [del(17)(p11.2p11.2)] Genet Med. 2003;5:430–4. doi: 10.1097/01.GIM.0000095625.14160.AB.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.GIM.0000095625.14160.AB</ArticleId>
            <ArticleId IdType="pubmed">14614393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boone PM, Reiter RJ, Glaze DG, Tan DX, Lupski JR, Potocki L. Abnormal circadian rhythm of melatonin in Smith–Magenis syndrome patients with RAI1 point mutations. Am J Med Genet A. 2011;155A:2024–7. doi: 10.1002/ajmg.a.34098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.a.34098</ArticleId>
            <ArticleId IdType="pmc">PMC3140606</ArticleId>
            <ArticleId IdType="pubmed">21739587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spruyt K, Braam W, Smits M, Curfs LM. Sleep complaints and the 24-h melatonin level in individuals with Smith–Magenis syndrome: assessment for effective intervention. CNS Neurosci Ther. 2016;22:928–35. 10.1111/cns.12653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6492880</ArticleId>
            <ArticleId IdType="pubmed">27743421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girirajan S, Vlangos CN, Szomju BB, Edelman E, Trevors CD, Dupuis L, et al.  Genotype-phenotype correlation in Smith–Magenis syndrome: evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. Genet Med. 2006;8:417–27. doi: 10.1097/01.gim.0000228215.32110.89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.gim.0000228215.32110.89</ArticleId>
            <ArticleId IdType="pubmed">16845274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams SR, Zies D, Mullegama SV, Grotewiel MS, Elsea SH. Smith–Magenis syndrome results in disruption of CLOCK gene transcription and reveals an integral role for RAI1 in the maintenance of circadian rhythmicity. Am J Hum Genet. 2012;90:941–9. doi: 10.1016/j.ajhg.2012.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2012.04.013</ArticleId>
            <ArticleId IdType="pmc">PMC3370274</ArticleId>
            <ArticleId IdType="pubmed">22578325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, et al.  Multi-disciplinary clinical study of Smith–Magenis syndrome (deletion 17p11.2) Am J Med Genet. 1996;62:247–54. doi: 10.1002/(SICI)1096-8628(19960329)62:3&lt;247::AID-AJMG9&gt;3.0.CO;2-Q.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-8628(19960329)62:3&lt;247::AID-AJMG9&gt;3.0.CO;2-Q</ArticleId>
            <ArticleId IdType="pubmed">8882782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith AC, Dykens E, Greenberg F. Sleep disturbance in Smith–Magenis syndrome (del 17 p11.2) Am J Med Genet. 1998;81:186–91. doi: 10.1002/(SICI)1096-8628(19980328)81:2&lt;186::AID-AJMG11&gt;3.0.CO;2-D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-8628(19980328)81:2&lt;186::AID-AJMG11&gt;3.0.CO;2-D</ArticleId>
            <ArticleId IdType="pubmed">9613860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potocki L, Glaze D, Tan DX, Park SS, Kashork CD, Shaffer LG, et al.  Circadian rhythm abnormalities of melatonin in Smith–Magenis syndrome. J Med Genet. 2000;37:428–33. doi: 10.1136/jmg.37.6.428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.37.6.428</ArticleId>
            <ArticleId IdType="pmc">PMC1734604</ArticleId>
            <ArticleId IdType="pubmed">10851253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Leersnyder H, de Blois M-C, Claustrat B, Romana S, Albrecht U, Von Kleist-Retzow JC, et al.  Inversion of the circadian rhythm of melatonin in the Smith–Magenis syndrome. J Pediatr. 2001;139:111–6. doi: 10.1067/mpd.2001.115018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mpd.2001.115018</ArticleId>
            <ArticleId IdType="pubmed">11445803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith ACM, Duncan WC. Smith–Magenis syndrome—a developmental disorder with circadian dysfunction. In: Genetics of developmental disabilities. Boca Raton, FL: Taylor &amp; Francis; 2005.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith ACM, Morse RS, Introne W, Duncan WC. Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith–Magenis syndrome, a neurodevelopmental disorder. Am J Med Genet Part A. 2019;179:224–36. doi: 10.1002/ajmg.a.61003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.a.61003</ArticleId>
            <ArticleId IdType="pmc">PMC6699156</ArticleId>
            <ArticleId IdType="pubmed">30690916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith ACM, Boyd KE, Brennan C, et al. Medical management guidelines for an individual diagnosed with SMS. PRISMS. Retrieved from https://www.prisms.org/wpcontent/uploads/pdf/mmg/PRISMS_Medical_Management_Guidelines2018.pdf. 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Laje G, Morse R, Richter W, Ball J, Pao M, Smith ACM. Autism spectrum features in Smith–Magenis syndrome. Am J Med Genet Part C Semin Med Genet. 2010;154:456–62. doi: 10.1002/ajmg.c.30275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.c.30275</ArticleId>
            <ArticleId IdType="pmc">PMC2967410</ArticleId>
            <ArticleId IdType="pubmed">20981775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith ACM, Boyd KE, Elsea SH, et al. Smith–Magenis syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews. Seattle: University of Washington; 1993.</Citation>
        </Reference>
        <Reference>
          <Citation>Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, et al.  Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373:482–91. doi: 10.1016/S0140-6736(08)61812-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(08)61812-7</ArticleId>
            <ArticleId IdType="pubmed">19054552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386:1754–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26466871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polymeropoulos CM, Mohrman MA, Keefe MS, Brzezynski JL, Wang J, Prokosch LS, et al.  Efficacy of tasimelteon (HETLIOZ®) in the treatment of jet lag disorder evaluated in an 8-h phase advance model; a multicenter, randomized, double-blind, placebo-controlled trial. Front Neurol. 2020;11:1–10. doi: 10.3389/fneur.2020.00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00001</ArticleId>
            <ArticleId IdType="pmc">PMC7381312</ArticleId>
            <ArticleId IdType="pubmed">32754110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry. 2007;4:28–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880930</ArticleId>
            <ArticleId IdType="pubmed">20526405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3993694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroder CM, Malow BA, Maras A, Melmed RD, Findling RL, Breddy J, et al.  Pediatric prolonged-release melatonin for sleep in children with autism spectrum disorder: impact on child behavior and caregiver’s quality of life. J Autism Dev Disord. 2019;49:3218–30. doi: 10.1007/s10803-019-04046-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10803-019-04046-5</ArticleId>
            <ArticleId IdType="pmc">PMC6647439</ArticleId>
            <ArticleId IdType="pubmed">31079275</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
